Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates

Research ArticleBrain
Open Access

No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis

R. Zivadinov, G. Cutter, K. Marr, M. Ramanathan, R.H.B. Benedict, N. Bergsland, C. Morgan, E. Carl, D. Hojnacki, E.A. Yeh, L. Willis, M. Cherneva, C. Kennedy, M.G. Dwyer and B. Weinstock-Guttman
American Journal of Neuroradiology November 2012, 33 (10) 1913-1917; DOI: https://doi.org/10.3174/ajnr.A3112
R. Zivadinov
aFrom the Buffalo Neuroimaging Analysis Center (R.Z., K.M., N.B., E.C., L.W., M.C., C.K., M.G.D.)
bThe Jacobs Neurological Institute, Department of Neurology (R.Z., R.H.B.B., D.H., E.A.Y., B.W.-G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Cutter
dDepartment of Biostatistics (G.C., C.M.), University of Alabama, Birmingham, Alabama.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Marr
aFrom the Buffalo Neuroimaging Analysis Center (R.Z., K.M., N.B., E.C., L.W., M.C., C.K., M.G.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Ramanathan
cDepartment of Pharmaceutical Sciences (M.R.), State University of New York, Buffalo, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R.H.B. Benedict
bThe Jacobs Neurological Institute, Department of Neurology (R.Z., R.H.B.B., D.H., E.A.Y., B.W.-G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Bergsland
aFrom the Buffalo Neuroimaging Analysis Center (R.Z., K.M., N.B., E.C., L.W., M.C., C.K., M.G.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Morgan
dDepartment of Biostatistics (G.C., C.M.), University of Alabama, Birmingham, Alabama.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Carl
aFrom the Buffalo Neuroimaging Analysis Center (R.Z., K.M., N.B., E.C., L.W., M.C., C.K., M.G.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Hojnacki
bThe Jacobs Neurological Institute, Department of Neurology (R.Z., R.H.B.B., D.H., E.A.Y., B.W.-G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E.A. Yeh
bThe Jacobs Neurological Institute, Department of Neurology (R.Z., R.H.B.B., D.H., E.A.Y., B.W.-G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Willis
aFrom the Buffalo Neuroimaging Analysis Center (R.Z., K.M., N.B., E.C., L.W., M.C., C.K., M.G.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Cherneva
aFrom the Buffalo Neuroimaging Analysis Center (R.Z., K.M., N.B., E.C., L.W., M.C., C.K., M.G.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Kennedy
aFrom the Buffalo Neuroimaging Analysis Center (R.Z., K.M., N.B., E.C., L.W., M.C., C.K., M.G.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.G. Dwyer
aFrom the Buffalo Neuroimaging Analysis Center (R.Z., K.M., N.B., E.C., L.W., M.C., C.K., M.G.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Weinstock-Guttman
bThe Jacobs Neurological Institute, Department of Neurology (R.Z., R.H.B.B., D.H., E.A.Y., B.W.-G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Abstract

BACKGROUND AND PURPOSE: CCSVI has been reported to occur at high frequency in MS. Its significance in relation to MR imaging parameters also needs to be determined, both in patients with MS and HCs. Therefore, this study determined the associations of CCSVI and conventional MR imaging outcomes in patients with MS and in HCs.

MATERIALS AND METHODS: T2, T1, and gadolinium lesion number, LV, and brain atrophy were assessed on 3T MR imaging in 301 subjects, of whom 162 had RRMS, 66 had secondary-progressive MS subtype, and 73 were HCs. CCSVI was assessed using extracranial and transcranial Doppler evaluation. The MR imaging measure differences were explored with 27 borderline cases for CCSVI, added to both the negative and positive CCSVI groups to assess sensitivity of the results of these cases.

RESULTS: No significant differences between subjects with and without CCSVI were found in any of the individual diagnostic subgroups or MS disease subtypes for lesion burden and atrophy measures, independently of the CCSVI classification criteria used, except for a trend for higher T2 lesion number (irrespective of how borderline cases were classified) and lower brain volume (when borderline cases were included in the positive group) in patients with RRMS with CCSVI. No CCSVI or MR imaging differences were found between 26 HCs with, or 47 without, a familial relationship.

CONCLUSIONS: CCSVI is not associated with more severe lesion burden or brain atrophy in patients with MS or in HCs.

ABBREVIATIONS:

CCSVI
chronic cerebrospinal venous insufficiency
CIS
clinically isolated syndrome
CTEVD
Combined Transcranial and Extracranial Venous Doppler
EDSS
Expanded Disability Status Scale
HC
healthy control
LV
lesion volume
RRMS
relapsing-remitting MS
SPMS
secondary-progressive MS

MS is primarily considered a chronic inflammatory disease of the CNS characterized by inflammation, demyelination, and neurodegeneration, mediated mainly by T- and B-cells.1

CCSVI has been reported to occur at high frequency in MS.2,3 CCSVI was originally described as a vascular condition characterized by anomalies of the main extracranial cerebrospinal venous routes that interfere with normal blood outflow in patients with MS.2⇓–4

The concept of CCSVI in patients with MS, and its possible implications for MS pathogenesis and treatment options, has raised significant interest in both the patient5 and medical communities.6⇓–8 Some recent studies were able to partially reproduce original findings2⇓–4 with substantially lower sensitivity and specificity for MS,9⇓⇓⇓⇓⇓⇓⇓–17 while others were not able to support these findings using various imaging techniques.18⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓–29

In the CTEVD study,13 the largest case-control study, to date, to investigate the prevalence of CCSVI in patients with MS, CIS, and other neurologic diseases, and HCs using specific proposed Doppler sonography criteria,3 increased prevalence of CCSVI in MS was shown but with modest sensitivity and specificity. Despite the currently ongoing debate about whether CCSVI is associated with MS or not,30 its significance in relation to MR imaging parameters also needs to be determined, both in patients with MS and HCs. In this study, the associations between the presence of CCSVI and conventional MR imaging measures (lesion burden and brain atrophy) in a large cohort of patients with MS and HCs has been investigated.

Materials and Methods

This study was a single-center, cross-sectional, observer-masked study that included 499 subjects.13 Inclusion criteria for this study were patients with RRMS and secondary-progressive disease course, or HCs, having an MR imaging examination performed within 30 days of Doppler examination with the standardized study protocol. Exclusion criteria were presence of relapse and steroid treatment in the 30 days preceding study entry for all patients, pre-existing medical conditions known to be associated with brain pathology (eg, cerebrovascular disease, positive history of alcohol abuse), known history of cerebral congenital vascular malformations, and pregnancy. HCs were recruited from the following volunteer sources: hospital personnel, respondents to a local advertisement, and spouses or relatives of the patients with MS. HCs needed to complete a health screening questionnaire containing information about medical history (illnesses, surgeries, medications, etc) and needed to meet the health-screen requirements on physical examination.

Participants underwent a clinical and MR imaging examination and transcranial and extracranial Doppler scans of the head and neck. Standard demographic and clinical information on all participating subjects was acquired via a structured questionnaire and by examination. The Doppler evaluators were blinded to the subjects' status, as previously described.13 In particular, subjects were specifically instructed not to reveal their disease status during the Doppler examination. Patients with other neurologic diseases and CIS were not part of this CTEVD MR imaging substudy but were used as part of the overall population to ensure blinding in the CTEVD study. The MR imaging evaluators were completely blinded to subject disease and clinical and CCSVI status. The study was approved by the local institutional review board and informed consent was obtained from all subjects.

Doppler Sonography

The Doppler examination was performed by using MyLab 25 Gold sonography machine (Esaote, Indianapolis, Indiana) equipped with 2.5 and 7.5–10 MHz transducers and motorized chair capable of tilting from 0° to 90°. All study examinations were performed by the same Doppler technologist. We examined Doppler parameters that detect 5 anomalous venous hemodynamic criteria affecting cerebrospinal venous return. More specific discussions on subject, length of examination, contraindications and limitations, specific Doppler parameters, criteria definitions, description of probes, positioning of the subject, techniques used, fulfillment of venous hemodynamic criteria and pathology definitions is provided elsewhere.13

Each subject was assigned a total venous hemodynamic criteria score, calculated by counting the number of criteria that the subject fulfilled. A subject was considered CCSVI-positive if ≥2 venous hemodynamic criteria were fulfilled, as previously proposed.3 Subjects who were not assessed for a venous hemodynamic criterion, due to technical difficulty, were assumed not to have fulfilled that criterion.13 Subjects who fulfilled exactly 1 of the other 4 criteria and were not assessed on 1 venous hemodynamic criterion were classified as CCSVI-borderline.13

MR Imaging Acquisition and Analysis

All subjects were examined on a 3T Signa Excite HD 12.0 Twin Speed 8-channel scanner (GE Healthcare, Milwaukee, Wisconsin). The following sequences were acquired: 2D multiplanar dual FSE proton-attenuation and T2WI; FLAIR; 3D high-resolution T1WI using fast-spoiled gradient echo with magnetization-prepared inversion recovery pulse; spin-echo T1WI, both with and without a single dose intravenous bolus of 0.1 mMol/Kg gadolinium-diethylene triamine pentaacetic acid, 5 minutes after injection (only in patients with MS).

One average was used for all pulse sequences. All sequences were acquired with a 256 × 192 matrix (freq × phase) and FOV of 25.6 cm × 19.2 cm (256 × 256 matrix with phase FOV = 0.75), for an in-plane resolution of 1 mm × 1 mm. For all 2D scans (proton-attenuation/T2, FLAIR, and spin-echo T1), 48 sections were collected, with a thickness of 3 mm, and no gap between sections. For the 3D high-resolution inversion recovery fast-spoiled gradient echo, 128 locations were acquired, 1.5 mm thick. Other relevant parameters were as follows: for dual FSE proton-attenuation/T2, TE1/TE2/TR = 9 /98/5300 ms, flip angle = 90, echo-train length = 14; for FLAIR, TE/TI/TR = 120/2100/8500 ms (TI-inversion time), flip angle = 90, echo-train length = 24; for spin-echo T1WI, TE/TR = 16/600 ms, flip angle = 90; and for 3D high-resolution T1WI, TE/TI/TR = 2.8/900/5.9 ms, flip angle = 10. Scans were prescribed in an axial-oblique orientation, parallel to the subcallosal line.

Lesion Measures.

The T2-, T1-, and gadolinium number and LVs were measured using a semiautomated edge detection contouring/thresholding technique previously described.31

Global and Regional Atrophy Measures.

For brain extraction and tissue segmentation into gray matter and white matter, the SIENAX cross-sectional software tool was used (version 2.6; www.fmrib.ox.ac.uk/fsl/siena), with corrections for T1-hypointensity misclassification by using an in-house developed in-painting program.32 Normalized volumes of the whole brain, gray matter volume, cortical volume, and white matter volume were assessed as previously described.33 In addition, we calculated central atrophy measures, including normalized lateral ventricle volume and third ventricle width.34

Statistical Analyses

Statistical analyses were performed using the R software package (version 2.8.1; http://www.r-project.org) and SAS (version 9.3; SAS, Cary, North Carolina). For comparing demographic, clinical, and MR imaging characteristics between the study groups, t tests, Fisher exact tests, and χ2 tests were used. For MR imaging measures that were based on volumes (LVs and SIENAX normalized volumes), the cube root was taken before conducting statistical analyses. The MR imaging volumetric results are expressed in milliliters.

To test the impact of the CCSVI-borderline cases on the MR imaging findings, the differences were explored with the borderline cases for CCSVI first analyzed in the negative group and then the analyses repeated, including them in the positive CCSVI group.

Due to multiple comparisons, a nominal P value <.01 was considered statistically significant using 2-tailed tests.

Results

Demographic and Clinical Characteristics

In total, 301 (60.3%) patients were included in this MR imaging substudy. Of the 499 subjects participating in the study, 361 (72.3%) subjects had an MR imaging examination performed with the standard MR imaging study protocol. The other 138 (27.7%) subjects did not undergo an MR imaging examination with the standard study protocol, mostly because of lack of scanner availability within the time recruitment window. Of the 361 subjects who underwent MR imaging with the standard study protocol, 10 (2.8%) subjects had MR imaging scans of insufficient quality to perform quantitative analysis. For simplicity, subgroups too small to include as separate categories in this study were excluded, as per inclusion criteria. These were 20 patients with CIS, 18 with other neurologic diseases, 10 with primary-progressive MS, 1 with progressive-relapsing disease, and 1 with neuromyelitis optica. The median number of days between Doppler sonography and MR imaging examination was 2 (minimum = 0, maximum = 30).

Demographic and clinical characteristics of the MR imaging participants are presented in Table 1. Of the 73 HCs participating in this MR imaging substudy, 27 (37%) were recruited from hospital personnel and/or local advertisement, 20 (27.4%) were spouses of patients with MS, and 26 (35.6%) were relatives of the patients. There were significantly more females in the MS compared with the HC group (P = .002); however, no sex differences were observed between the sources of HC recruitment (P = .66). As expected, secondary-progressive patients had higher age, disease duration, and EDSS scores (all P < .0001) compared with the RRMS group.

View this table:
  • View inline
  • View popup
Table 1:

Demographic and clinical characteristics of the enrolled disease group subtypes

There were no significant age, sex, disease duration, or EDSS differences between those who were enrolled in this MR imaging substudy of the CTEVD (n = 301) and those who were not (n = 198; data not shown).

CCSVI Status Assessment

Of the 73 HCs, 19 (26%) were CCSVI-positive and 6 (8.2%) were CCSVI-borderline. No significant differences in CCSVI status were found with respect to the source of HC recruitment (familial versus spouse versus other). No significant age or sex differences in respect to CCSVI status were found in HCs.

Of the 228 patients with MS, 131 (57.5%) were CCSVI-positive and 21 (9.2%) were CCSVI-borderline. The figures were 81 (50%) and 19 (11.7%) in the RRMS, and 50 (75.8%) and 2 (3.2%) in the SPMS groups (P = .001). In patients with MS, there was no significant difference in mean age (46.3 versus 44.8 years; P = .39), sex ratio (77.8% versus 78.4% female; P = .53), or disease duration (14.6 versus 13.2 years; P = .35) between subjects with CCSVI and those without.

Lesion Number and Volume Differences According to the CCSVI Status

On-line Tables 1 and 2 show lesion number and LV differences by individual diagnostic subgroups according to CCSVI status, in which the borderline cases were included in the negative or positive CCSVI groups. No significant differences were found between CCSVI-positive and -negative subjects for lesion number and LV (T2, T1, and gadolinium) in individual diagnostic subgroups or MS disease subtypes, except for a trend for higher T2 lesion number in patients with RRMS with CCSVI compared with those without (CCSVI-borderline included in the positive CCSVI group, P = .04, and CCSVI-borderline included in the negative CCSVI group, P = .05).

No lesion differences were observed, according to CCSVI status, in 47 nonfamilial versus 26 familial HCs.

Global and Regional Atrophy Differences According to the CCSVI Status

On-line Tables 3 and 4 show global and regional atrophy differences by individual diagnostic subgroups according to CCSVI status, in which the borderline cases were included in the negative or positive CCSVI groups. No significant differences were found between CCSVI-positive and -negative subjects for global and regional atrophy measures in individual diagnostic subgroups or MS disease subtypes, except for a trend for lower normalized volume of the whole brain in patients with RRMS with CCSVI compared with those without, when CCSVI-borderline cases were included in the positive CCSVI group (P = .06).

No atrophy differences were observed, according to CCSVI status, in 47 nonfamilial versus 26 familial HCs.

Discussion

This is the first large study to investigate the relationship between extracranial venous hemodynamic alterations and intracranial MS pathology, as assessed by conventional MR imaging measures. The presence of CCSVI was not significantly related to more severe lesion burden and brain atrophy in individual diagnostic subgroups or MS disease subtypes.

A case-control rater-blinded study showed that there is an increased prevalence of CCSVI in MS, but with modest sensitivity and specificity.13 In this MR imaging substudy, 60.3% of the participating subjects, who received standardized 3T MR imaging, were included. Similar prevalence rates of CCSVI in this MR imaging substudy were found, as in the previous study.13

A number of recent reports have presented evidence against the CCSVI hypothesis in MS.18⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓–29 The possible reasons for the discrepancies in findings between different studies are numerous.30 Veins have a tendency to collapse and change their morphology and size. Because of this, it is complex to study the intracranial and cervical venous systems, regardless of the imaging technique used. No established standardized guidelines for detection of extracranial venous abnormalities indicative of CCSVI currently exist, though there is common knowledge among radiologists about how to perform diagnostic imaging and intervention on the extracranial veins However, the value of Doppler sonography, in properly trained hands, for screening of CCSVI was tested against reference-standard catheter venography in 2 recent pilot studies in patients with MS and HCs, with promising results.10,35 In one of these studies, Doppler sonography showed 82% sensitivity and 100% specificity compared with catheter venography in 10 patients with MS.35 In another recent study, using 2 different noninvasive imaging techniques, it was shown that patients with progressive MS presented with significantly more extraluminal Doppler sonography abnormalities and more flow abnormalities on MR venography than patients with nonprogressive MS.14 A multimodal approach is recommended to determine whether CCSVI exists and to what extent it is present in various healthy and disease groups, and MS subtypes.30

Recent opinion papers6,7 have discussed the urgent need to demonstrate whether the presence of CCSVI in MS may be related to disease etiology and severity, including MR imaging outcomes. At this time, it is unknown whether altered extracranial venous hemodynamic outflow may contribute to inflammatory/neurodegenerative damage in MS. No association was found between CCSVI status in individual diagnostic subgroups or MS disease subtypes, independent of whether CCSVI-borderline cases were included in the negative or positive CCSVI groups. Only patients with RRMS showed a trend for a higher number of T2 lesions among patients with CCSVI, independent of the CCSVI-borderline classification. These findings warrant further investigation but firmly suggest that if CCSVI contributes to higher lesion burden in patients with MS, then this effect is probably weak, given the relatively large MS sample size used for this MR imaging substudy (228 patients with MS). No lesion burden differences were found in patients with SPMS, both with and without CCSVI, suggesting that if CCSVI contributes to more progressive disease, then this effect is not mediated by the relationship between CCSVI and accumulation of inflammatory lesions.

Although we did not find a relationship between age and the diagnosis of CCSVI either in HCs or in the entire MS group, it cannot be excluded that the prevalence of these abnormalities is aging-dependent. A recent study that investigated internal jugular vein changes with aging in HCs found a decreased proportion of venous drainage and increased internal jugular vein reflux prevalence in older subjects.36 Even more recently, the same group of investigators showed that subjects with severe internal jugular vein reflux had more severe age-related WM changes on MR imaging, especially in caudal brain regions.37 Therefore, the effect of CCSVI-related abnormalities in relation to WM changes in the brain parenchyma has to be further investigated.

No significant differences in global or regional atrophy measures were found between those with and without the presence of CCSVI, independent of whether CCSVI-borderline cases were included in the negative or positive CCSVI groups. Only patients with RRMS showed a trend for lower whole-brain volume among patients with CCSVI, when CCSVI-borderline cases were included in the CCSVI-positive group. Therefore, we did not confirm results of a previous small pilot study where we found a significant relationship between a higher number of pathologic venous hemodynamic criteria and decreased brain volume.38

While fulfillment of ≥2 CCSVI-proposed Doppler criteria reflects the present definition of CCSVI,3 it does not reflect its severity. To decrease the number of comparisons between the study groups with respect to their MR imaging outcomes, we decided to use only the CCSVI status in our analyses. This conservative approach should have avoided possible over-interpretation of the study findings.

No significant differences in age, CCSVI status, and source of recruitment were found between men and women in the HC group. Neither were there detected significant differences in CCSVI status and MR imaging characteristics between the HCs who presented with familial MS and those with nonfamilial MS. The results of these analyses are in line with those reported in the previous study,13 and are corroborated by the lack of strong associations between CCSVI and HLA DRB1*1501,39 which suggests that the role of the underlying genetic associations of CCSVI should be interpreted with caution.

There are number of potential limitations of this study. There were significantly fewer women in the HC group compared with patients with MS. Of the 499 subjects participating in the study, 39.7% were excluded in this MR imaging substudy. This is mostly because of lack of scanner availability within the time recruitment window, and because the analysis was restricted to subject groups with substantial sample size, to enable analyses comparable between the groups, and consequently smaller MS disease subgroups were excluded.

Conclusions

The lack of association between CCSVI and lesion burden and brain atrophy findings, signatures of the inflammatory and neurodegenerative processes, point against CCSVI having an important role in the accumulation of lesion burden and brain atrophy in patients with MS or in HCs.

Footnotes

  • Disclosures: This study was funded by internal resources of the Buffalo Neuroimaging Analysis Center and Baird MS Center, the Jacobs Neurological Institute, University of Buffalo. In addition, we received support from the Direct MS Foundation, the Jacquemin Family Foundation, and from smaller donors. Gary Cutter received consulting and speaking fees, and serves on the following advisory boards: Lexion, Bayhill, Bayer, Novartis, Consortium of MS Centers (grant), Klein-Buendel Incorporated, Peptimmune, Somnus Pharmaceuticals, Sandoz, Teva pharmaceuticals, UT Southwestern, Visioneering Technologies, Inc. Unrelated ICMJE Disclosures: Participation of Data and Safety Monitoring Committees: Apotek, Sanofi-Aventis, Biogen, Cleveland Clinic, Daichi-Sankyo, Glaxo Smith Klein Pharmaceuticals, Genmab Biopharmaceuticals, EliLilly, Medivation, Modigenetech, Ono Pharmaceuticals, Teva, NHLBI, NINDS, NMSS; Consulting, Speaking Fees, and Advisory Boards: Alexion, Abbott, Bayer, Coronado Biosciences, Novartis, Consortium of MS Centers (grant), Genzyme, Klein-Buendel Incorporated, Nuron Biotech, Peptimmune, Receptos, Somnus Pharmaceuticals, Teva pharmaceuticals, St. Louis University; Grants/Grants Pending: NINDS. Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: see above; Karen Marr—UNRELATED: Payment for Lectures (including service on speakers bureaus): Vascular Access; Murali Ramanathan served as an editor for the American Association of Pharmaceutical Scientists Journal; receives royalties for publishing The Pharmacy Calculations Workbook [Pinnacle, Summit and Zenith, 2008]; and receives research support from EMD Serono, Novartis, Pfizer, the National Multiple Sclerosis Society, and the National Science Foundation. Unrelated ICMJE Disclosures: Consultancy: Allergan, Netezza; Payment for Development of Educational Presentations: Wrote a pharmaceutical sciences paper; Ralph HB Benedict received research support from Biogen Idec and Shire Inc, and serves on advisory panels for Bayer, Biogen, Novartis, Merck Serono, and Pfizer; Charity Morgan—RELATED: Grant: National Institute of Neurological Disorders and Stroke*; David Hojnacki has received speaker honoraria and consultant fees from Biogen Idec, Teva Pharmaceutical Industries Ltd., EMD Serono, Pfizer Inc, and Novartis; Eluen Ann Yeh—RELATED: NMSS Pediatric MS Centers of Excellence Grant, Comments: This was a center grant for clinical care of children with MR; Bianca Weinstock- Guttman received honoraria as a speaker and as a consultant for Biogen Idec, TEVA, EMD Serono, Pfizer, Novartis and Acorda. Dr Weinstock-Guttman received research funds from Biogen Idec, TEVA, EMD Serono, Pfizer, ITN, Shire, Novartis, Acorda and Cyberonics; Robert Zivadinov received personal compensation from Teva Neuroscience, Biogen Idec, EMD Serono and Questcor Pharmaceuticals for speaking and consultant fees. Dr. Zivadinov received financial support for research activities from Biogen Idec, Teva Neuroscience, Genzyme, Bracco, Questcor Pharmaceuticals and EMD Serono. Related ICMJE Disclosure: Direct MS Foundation,* Jacquemin Family Foundation.* (*Money paid to institution)

Indicates open access to non-subscribers at www.ajnr.org

References

  1. 1.↵
    1. Frohman EM,
    2. Racke MK,
    3. Raine CS
    . Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med 2006;354:942–55
    CrossRefPubMed
  2. 2.↵
    1. Zamboni P,
    2. Galeotti R,
    3. Menegatti E,
    4. et al
    . A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg 2009;50:1348–58, e1–3
    CrossRefPubMed
  3. 3.↵
    1. Zamboni P,
    2. Galeotti R,
    3. Menegatti E,
    4. et al
    . Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:392–99
    Abstract/FREE Full Text
  4. 4.↵
    1. Zamboni P,
    2. Menegatti E,
    3. Galeotti R,
    4. et al
    . The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis. J Neurol Sci 2009;282:21–27
    CrossRefPubMed
  5. 5.↵
    1. Barkhouse M
    . Why can't I get my veins unblocked in Canada? Can Med Assoc J 2010;182:1214
    FREE Full Text
  6. 6.↵
    1. Rudick RA
    . Multiple sclerosis: is multiple sclerosis caused by venous insufficiency? Nat Rev Neurol 2010;6:472–74
    CrossRefPubMed
  7. 7.↵
    1. Khan O,
    2. Filippi M,
    3. Freedman MS,
    4. et al
    . Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol 2010;67:286–90
    CrossRefPubMed
  8. 8.↵
    1. D'haeseleer M,
    2. Cambron M,
    3. Vanopdenbosch L,
    4. et al
    . Vascular aspects of multiple sclerosis. Lancet Neurol 2011;10:657–66
    CrossRefPubMed
  9. 9.↵
    1. Al-Omari MH,
    2. Rousan LA
    . Internal jugular vein morphology and hemodynamics in patients with multiple sclerosis. Int Angiol 2010;29:115–20
    PubMed
  10. 10.↵
    1. Hojnacki D,
    2. Zamboni P,
    3. Lopez-Soriano A,
    4. et al
    . Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. Int Angiol 2010;29:127–39
    PubMed
  11. 11.↵
    1. Simka M,
    2. Kostecki J,
    3. Zaniewski M,
    4. et al
    . Extracranial Doppler sonographic criteria of chronic cerebrospinal venous insufficiency in the patients with multiple sclerosis. Int Angiol 2010;29:109–14
    PubMed
  12. 12.↵
    1. Yamout B,
    2. Herlopian A,
    3. Issa Z,
    4. et al
    . Extracranial venous stenosis is an unlikely cause of multiple sclerosis. Mult Scler 2010;16:1341–48
    Abstract/FREE Full Text
  13. 13.↵
    1. Zivadinov R,
    2. Marr K,
    3. Cutter G,
    4. et al
    . Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology 2011;77:138–44
    Abstract/FREE Full Text
  14. 14.↵
    1. Dolic K,
    2. Marr K,
    3. Valnarov V,
    4. et al
    . Intra- and extraluminal structural and functional venous anomalies in multiple sclerosis, as evidenced by 2 non-invasive imaging techniques. AJNR Am J Neuroradiol 2012;33:16–23
    Abstract/FREE Full Text
  15. 15.↵
    1. Monti L,
    2. Menci E,
    3. Ulivelli M,
    4. et al
    . Quantitative ColourDopplerSonography evaluation of cerebral venous outflow: a comparative study between patients with multiple sclerosis and controls. PLoS One 2011;6:e25012
    CrossRefPubMed
  16. 16.↵
    1. Zaharchuk G,
    2. Fischbein NJ,
    3. Rosenberg J,
    4. et al
    . Comparison of MR and contrast venography of the cervical venous system in multiple sclerosis. AJNR Am J Neuroradiol 2011;32:1482–89
    Abstract/FREE Full Text
  17. 17.↵
    1. Radak D,
    2. Kolar J,
    3. Tanaskovic S,
    4. et al
    . Morphological and haemodynamic abnormalities in the jugular veins of patients with multiple sclerosis. Phlebology 2012;27:168–72
    Abstract/FREE Full Text
  18. 18.↵
    1. Wattjes MP,
    2. van Oosten BW,
    3. de Graaf WL,
    4. et al
    . No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. J Neurol Neurosurg Psychiatry 2011;82:429–35
    Abstract/FREE Full Text
  19. 19.↵
    1. Sundström P,
    2. Wahlin A,
    3. Ambarki K,
    4. et al
    . Venous and cerebrospinal fluid flow in multiple sclerosis: a case-control study. Ann Neurol 2010;68:255–59
    CrossRefPubMed
  20. 20.↵
    1. Doepp F,
    2. Paul F,
    3. Valdueza JM,
    4. et al
    . No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol 2010;68:173–83
    PubMed
  21. 21.↵
    1. Krogias C,
    2. Schroder A,
    3. Wiendl H,
    4. et al
    . [“Chronic cerebrospinal venous insufficiency” and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt 2010;81:740–46
    CrossRefPubMed
  22. 22.↵
    1. Mayer CA,
    2. Pfeilschifter W,
    3. Lorenz MW,
    4. et al
    . The perfect crime? CCSVI not leaving a trace in MS. J Neurol Neurosurg Psychiatry 2011;82:436–40
    Abstract/FREE Full Text
  23. 23.↵
    1. Baracchini C,
    2. Perini P,
    3. Calabrese M,
    4. et al
    . No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Ann Neurol 2011;69:90–99
    CrossRefPubMed
  24. 24.↵
    1. Zivadinov R,
    2. Lopez-Soriano A,
    3. Weinstock-Guttman B,
    4. et al
    . Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. Radiology 2011;258:562–70
    CrossRefPubMed
  25. 25.↵
    1. Centonze D,
    2. Floris R,
    3. Stefanini M,
    4. et al
    . Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity. Ann Neurol 2011;70:52–59
    CrossRef
  26. 26.↵
    1. Auriel E,
    2. Karni A,
    3. Bornstein NM,
    4. et al
    . Extra-cranial venous flow in patients with multiple sclerosis. J Neurol Sci 2011;309:102–04
    CrossRefPubMed
  27. 27.↵
    1. Baracchini C,
    2. Perini P,
    3. Causin F,
    4. et al
    . Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency. Neurology 2011;77:844–50
    Abstract/FREE Full Text
  28. 28.↵
    1. Doepp F,
    2. Wurfel JT,
    3. Pfueller CF,
    4. et al
    . Venous drainage in multiple sclerosis: a combined MRI and ultrasound study. Neurology 2011;77:1745–51
    Abstract/FREE Full Text
  29. 29.↵
    1. Tsivgoulis G,
    2. Mantatzis M,
    3. Bogiatzi C,
    4. et al
    . Extracranial venous hemodynamics in multiple sclerosis: a case-control study. Neurology 2011;77:1241–45
    Abstract/FREE Full Text
  30. 30.↵
    1. Zivadinov R,
    2. Ramanathan M,
    3. Dolic K,
    4. et al
    . Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Rev Neurother 2011;11:1277–94
    CrossRefPubMed
  31. 31.↵
    1. Zivadinov R,
    2. Rudick RA,
    3. De Masi R,
    4. et al
    . Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239–47
    Abstract/FREE Full Text
  32. 32.↵
    1. Yeh E,
    2. Weinstock-Guttman B,
    3. Ramanathan M,
    4. et al
    . MRI characteristics of children and adults with pediatric-onset multiple sclerosis. Brain 2009;132:3392–400
    Abstract/FREE Full Text
  33. 33.↵
    1. Zivadinov R,
    2. Weinstock-Guttman B,
    3. Benedict R,
    4. et al
    . Preservation of gray matter volume in multiple sclerosis patients with the met allele of the rs6265 (Val66Met) SNP of brain derived neurotrophic factor (BDNF). Hum Mol Genet 2007;16:2659–68
    Abstract/FREE Full Text
  34. 34.↵
    1. Benedict R,
    2. Bruce J,
    3. Dwyer M,
    4. et al
    . Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006;63:1301–06
    CrossRefPubMed
  35. 35.↵
    1. Zivadinov R,
    2. Galeotti R,
    3. Hojnacki D,
    4. et al
    . Value of MR venography for detection of internal jugular vein anomalies in multiple sclerosis: a pilot longitudinal study. AJNR Am J Neuroradiol 2011;32:938–46
    Abstract/FREE Full Text
  36. 36.↵
    1. Chung C,
    2. Lin Y,
    3. Chao A,
    4. et al
    . Jugular venous hemodynamic changes with aging. Ultrasound Med Biol 2010;36:1776–82
    CrossRefPubMed
  37. 37.↵
    1. Chung CP,
    2. Wang PN,
    3. Wu YH,
    4. et al
    . More severe white matter changes in the elderly with jugular venous reflux. Ann Neurol 2011;69:553–59
    CrossRefPubMed
  38. 38.↵
    1. Zamboni P,
    2. Menegatti E,
    3. Weinstock-Guttman B,
    4. et al
    . CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: a pilot study. Int Angiol 2010;29:140–48
    PubMed
  39. 39.↵
    1. Weinstock-Guttman B,
    2. Zivadinov R,
    3. Cutter G,
    4. et al
    . Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients. PLoS One 2011;6:e16802
    CrossRefPubMed
  • Received December 13, 2011.
  • Accepted after revision February 13, 2012.
  • © 2012 by American Journal of Neuroradiology
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 33 (10)
American Journal of Neuroradiology
Vol. 33, Issue 10
1 Nov 2012
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
R. Zivadinov, G. Cutter, K. Marr, M. Ramanathan, R.H.B. Benedict, N. Bergsland, C. Morgan, E. Carl, D. Hojnacki, E.A. Yeh, L. Willis, M. Cherneva, C. Kennedy, M.G. Dwyer, B. Weinstock-Guttman
No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis
American Journal of Neuroradiology Nov 2012, 33 (10) 1913-1917; DOI: 10.3174/ajnr.A3112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis
R. Zivadinov, G. Cutter, K. Marr, M. Ramanathan, R.H.B. Benedict, N. Bergsland, C. Morgan, E. Carl, D. Hojnacki, E.A. Yeh, L. Willis, M. Cherneva, C. Kennedy, M.G. Dwyer, B. Weinstock-Guttman
American Journal of Neuroradiology Nov 2012, 33 (10) 1913-1917; DOI: 10.3174/ajnr.A3112
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Phlebographic Study Does Not Show Differences Between Patients with MS and Control Subjects
  • Crossref (12)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow
    Clive B. Beggs, Christopher Magnano, Simon J. Shepherd, Karen Marr, Vesela Valnarov, David Hojnacki, Niels Bergsland, Pavel Belov, Steven Grisafi, Michael G. Dwyer, Ellen Carl, Bianca Weinstock‐Guttman, Robert Zivadinov
    Journal of Magnetic Resonance Imaging 2014 40 5
  • Changes of Cine Cerebrospinal Fluid Dynamics in Patients with Multiple Sclerosis Treated with Percutaneous Transluminal Angioplasty: A Case-control Study
    Robert Zivadinov, Christopher Magnano, Roberto Galeotti, Claudiu Schirda, Erica Menegatti, Bianca Weinstock-Guttman, Karen Marr, Ilaria Bartolomei, Jesper Hagemeier, Anna Maria Malagoni, David Hojnacki, Cheryl Kennedy, Ellen Carl, Clive Beggs, Fabrizio Salvi, Paolo Zamboni
    Journal of Vascular and Interventional Radiology 2013 24 6
  • Internal Jugular Veins Outflow in Patients with Multiple Sclerosis: A Catheter Venography Study
    Pierfrancesco Veroux, Alessia Giaquinta, Debora Perricone, Lorenzo Lupo, Flavia Gentile, Carla Virgilio, Anna Carbonaro, Concetta De Pasquale, Massimiliano Veroux
    Journal of Vascular and Interventional Radiology 2013 24 12
  • Dirty‐Appearing White Matter in the Brain is Associated with Altered Cerebrospinal Fluid Pulsatility and Hypertension in Individuals without Neurologic Disease
    Clive B. Beggs, Christopher Magnano, Simon J. Shepherd, Pavel Belov, Deepa P. Ramasamy, Jesper Hagemeier, Robert Zivadinov
    Journal of Neuroimaging 2016 26 1
  • Is there a link between the extracranial venous system and central nervous system pathology?
    Robert Zivadinov
    BMC Medicine 2013 11 1
  • Meta-Analysis of the Correlation Between Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis
    Brittany A. Zwischenberger, Mary M. Beasley, Daniel L. Davenport, Eleftherios S. Xenos
    Vascular and Endovascular Surgery 2013 47 8
  • Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients
    Clive B. Beggs, Christopher Magnano, Pavel Belov, Jacqueline Krawiecki, Deepa P. Ramasamy, Jesper Hagemeier, Robert Zivadinov, Fernando de Castro
    PLOS ONE 2016 11 5
  • “Liberation treatment” for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free
    Georgios Tsivgoulis, Simon Faissner, Konstantinos Voumvourakis, Aristeidis H. Katsanos, Nikos Triantafyllou, Nikolaos Grigoriadis, Ralf Gold, Christos Krogias
    Brain and Behavior 2015 5 1
  • Chronic cerebrospinal venous insufficiency is not associated with cognitive impairment in multiple sclerosis
    Ralph HB Benedict, Bianca Weinstock-Guttmam, Karen Marr, Vesela Valnarov, Cheryl Kennedy, Ellen Carl, Christina Brooks, David Hojnacki, Robert Zivadinov
    BMC Medicine 2013 11 1
  • MR Venography in Patients with Multiple Sclerosis and Correlation with Clinical and MRI Parameters
    Eytan Raz, Simona Pontecorvo, Veronica Barra, Beatrice Cavallo Marincola, Manuela Morreale, Emanuele Tinelli, Luca Saba, Pier Luigi Di Paolo, Alessandro Aceti, Carlo Catalano, Ada Francia, Francesca Caramia
    Journal of Neuroimaging 2014 24 5

More in this TOC Section

  • Progression of Microstructural Damage in Spinocerebellar Ataxia Type 2: A Longitudinal DTI Study
  • SWI or T2*: Which MRI Sequence to Use in the Detection of Cerebral Microbleeds? The Karolinska Imaging Dementia Study
  • Statin Therapy Does Not Affect the Radiographic and Clinical Profile of Patients with TIA and Minor Stroke
Show more Brain

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editor's Choice
  • Fellows' Journal Club
  • Letters to the Editor
  • Video Articles

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

More from AJNR

  • Trainee Corner
  • Imaging Protocols
  • MRI Safety Corner
  • Book Reviews

Multimedia

  • AJNR Podcasts
  • AJNR Scantastics

Resources

  • Turnaround Time
  • Submit a Manuscript
  • Submit a Video Article
  • Submit an eLetter to the Editor/Response
  • Manuscript Submission Guidelines
  • Statistical Tips
  • Fast Publishing of Accepted Manuscripts
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Author Policies
  • Become a Reviewer/Academy of Reviewers
  • News and Updates

About Us

  • About AJNR
  • Editorial Board
  • Editorial Board Alumni
  • Alerts
  • Permissions
  • Not an AJNR Subscriber? Join Now
  • Advertise with Us
  • Librarian Resources
  • Feedback
  • Terms and Conditions
  • AJNR Editorial Board Alumni

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire